Robert Rusche, MD
Internal Medicine · Evansville, INNPI 1437152808
Payments from drug & device makers
Across 174 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$328
- Pfizer$302
- Amgen$284
- Merck$267
- GSK$180
- Novartis$169
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,783100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $328 |
| Pfizer | 25 | $302 |
| Amgen | 18 | $284 |
| Merck | 16 | $267 |
| GSK | 9 | $180 |
| Novartis | 11 | $169 |
| Sumitomo Pharma America, Inc. | 9 | $156 |
| Otsuka America Pharmaceutical, Inc. | 7 | $142 |
| Lundbeck LLC | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $94 |
| Lilly USA, LLC | 5 | $88 |
| Mylan Specialty L.p. | 4 | $69 |
| AstraZeneca | 4 | $68 |
| Exact Sciences | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| AbbVie | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| GE HealthCare | 1 | $28 |
| Dexcom, Inc. | 2 | $27 |
| Tactile Systems Technology Inc | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| KCI USA, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$2,783 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $151,734 |
| EliquisApixaban | 204 | $151,567 |
| XareltoRivaroxaban | 125 | $92,962 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $78,704 |
| JanuviaSitagliptin Phosphate | 54 | $72,210 |
| FarxigaDapagliflozin Propanediol | 54 | $54,916 |
| TrulicityDulaglutide | 39 | $41,631 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $39,467 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $31,300 |
| JardianceEmpagliflozin | 32 | $29,203 |
| EntrestoSacubitril/Valsartan | 37 | $26,982 |
| LinzessLinaclotide | 33 | $24,276 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $23,563 |
| GemtesaVibegron | 61 | $19,218 |
| MyrbetriqMirabegron | 26 | $17,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $328 | $165,295137 claims |
| PfizerEliquis, Premarin | $302 | $158,909219 claims |
| Johnson & JohnsonXarelto | $14 | $92,962125 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $68 | $91,85492 claims |
| MerckJanuvia | $267 | $72,21054 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $88 | $58,32855 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $46,65854 claims |
| Boehringer IngelheimJardiance, Tradjenta | $13 | $38,67963 claims |
| NovartisEntresto | $169 | $26,98237 claims |
| AbbVieLinzess | $36 | $24,27633 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $156 | $19,21861 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $17,87926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Evansville
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.